Top

Supportive Care in Cancer

Published in:

01-08-2014 | Original Article

Influence of periodontitis on the experience of oral mucositis in cancer patients undergoing head and neck radiotherapy: a pilot study

Authors: Arlene Khaw, Sharon Liberali, Richard Logan, Dorothy Keefe, P. Mark Bartold

Published in: Supportive Care in Cancer | Issue 8/2014

Abstract

Background and aim

Periodontitis and radiation-induced oral mucositis are both inflammatory conditions which may be associated through a common underlying dysregulation of the inflammatory response. This pilot study aimed to determine whether the severity of oral mucositis is associated with the severity of periodontitis in cancer patients undergoing head and neck radiotherapy.

Materials and methods

In this pilot study, 41 patients met the inclusion criteria. The severity of oral mucositis was measured according to the WHO system. The severity of periodontitis was assessed clinically and radiographically. Gingival crevicular fluid was sampled and levels of eight cytokines were determined using a multiplexed bead immunoassay. Associations between radiation-induced oral mucositis and periodontitis were analysed using logistic and linear regression.

Results

There was a trend towards a greater proportion of periodontitis patients in the mucositis groups (grades = 1–4) than in the non-mucositis group (grade = 0). However, due to the small sample size of this pilot study, these trends were not statistically significant.

Conclusion

This pilot study did not demonstrate a positive statistical correlation between periodontitis experience and severity of radiation-induced oral mucositis. Nonetheless, a trend towards increased bone loss, pocket depth and clinical attachment levels was noted in patients with mucositis grades 1–4. Larger studies with more stringent inclusion criteria are now required to further investigate this possible relationship between periodontitis experience and severity of radiation-induced oral mucositis.

Sonis ST (2011) Oral mucositis. Anti-Cancer Drugs 22:607–612PubMedCrossRef

Denham JW, Peters LJ, Johansen J, Poulsen M, Lamb DS, Hindley A, O’Brien PC, Spry NA, Penniment M, Krawitz H, Williamson S, Bear J, Tripcony L (1999) Do acute mucosal reactions lead to consequential late reactions in patients with head and neck cancer? Radiother Oncol 52:157–164PubMedCrossRef

Sonis ST, Eilers JP, Epstein JB, LeVeque FG, Liggett WH Jr, Mulagha MT, Peterson DE, Rose AH, Schubert MM, Spijkervet FK, Wittes JP (1999) Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy. Mucositis Study Group. Cancer 85:2103–2113PubMedCrossRef

Vera-Llonch M, Oster G, Hagiwara M, Sonis S (2006) Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma. Cancer 106:329–336PubMedCrossRef

Rosenthal DI (2007) Consequences of mucositis-induced treatment breaks and dose reductions on head and neck cancer treatment outcomes. J Support Oncol 5:23–31PubMed

Sonis ST (2002) The biologic role for nuclear factor-kappaB in disease and its potential involvement in mucosal injury associated with anti-neoplastic therapy. Crit Rev Oral Biol Med 13:380–389PubMedCrossRef

Kornman KS (2008) Mapping the pathogenesis of periodontitis: a new look. J Periodontol 79:1560–1568PubMedCrossRef

Roberts-Thomson KF (2007) Chapter 5. Oral health status. In: Australia’s Dental Generations: The National Survey of Adult Oral Health 2004–06. Canberra: Australian Institute of Health and Welfare, (eds.) GD Slade, AJ Spencer & KF Roberts-Thomson, pp. 81–142.

Hugoson A, Sjodin B, Norderyd O (2008) Trends over 30 years, 1973–2003, in the prevalence and severity of periodontal disease. J Clin Periodontol 35:405–414PubMedCrossRef

10.

Eke PI, Dye BA, Wei L, Thornton-Evans GO, Genco RJ (2012) Prevalence of periodontitis in adults in the United States: 2009 and 2010. J Dent Res 91:914–920PubMedCrossRef

11.

Loos BG (2005) Systemic markers of inflammation in periodontitis. J Periodontol 76:2106–2115PubMedCrossRef

12.

Madianos PN, Bobetsis YA, Van Dyke TE (2010) Chapter 3: Infection and inflammation. In: Periodontal disease and overall health: a clinician’s guide, (eds.) RJ. Genco & RC. Williams. Professional Audience Communications, Inc.

13.

Golub LM, Payne JB, Reinhardt RA, Nieman G (2006) Can systemic diseases co-induce (not just exacerbate) periodontitis? A hypothetical “two-hit” model. J Dent Res 85:102–105PubMedCrossRef

14.

Bartold PM, Marino V, Cantley M, Haynes DR (2010) Effect of Porphyromonas gingivalis-induced inflammation on the development of rheumatoid arthritis. J Clin Periodontol 37:405–411PubMedCrossRef

15.

Lang NP, Tonetti MS (2003) Periodontal risk assessment (PRA) for patients in supportive periodontal therapy (SPT). Oral Health Prev Dent 1:7–16PubMed

16.

Silness J, Loe H (1964) Periodontal disease in pregnancy II. Correlation between oral hygiene and periodontal condition. Acta Odontol Scand 22:121–135PubMedCrossRef

17.

Mercado F, Marshall RI, Klestov AC, Bartold PM (2000) Is there a relationship between rheumatoid arthritis and periodontal disease? J Clin Periodontol 27:267–272PubMedCrossRef

18.

Trotti A, Bellm LA, Epstein JB, Frame D, Fuchs HJ, Gwede CK, Komaroff E, Nalysnyk L, Zilberberg MD (2003) Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol 66:253–262PubMedCrossRef

19.

Page RC, Eke PI (2007) Case definitions for use in population-based surveillance of periodontitis. J Periodontol 78(7 Suppl):1387–1399

20.

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer

21.

Scully C, Sonis S, Diz PD (2006) Oral mucositis. Oral Dis 12:229–241PubMedCrossRef

22.

Weissberg JB, Pillsbury H, Sasaki CT, Son YH, Fischer JJ (1983) High fractional dose irradiation of advanced head and neck cancer. Implications for combined radiotherapy and surgery. Arch Otolaryngol 109:98–102PubMedCrossRef

23.

Pinto LH, Canary PC, Araujo CM, Bacelar SC, Souhami L (1991) Prospective randomized trial comparing hyperfractionated versus conventional radiotherapy in stages III and IV oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 21:557–562PubMedCrossRef

24.

Horiot JC, Bontemps P, van den Bogaert W, Le Fur R, van den Weijngaert D, Bolla M, Bernier J, Lusinchi A, Stuschke M, Lopez-Torrecilla J, Begg AC, Pierart M, Collette L (1997) Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol 44:111–121PubMedCrossRef

25.

Horiot JC, Le Fur R, N’Guyen T, Chenal C, Schraub S, Alfonsi S, Gardani G, Van Den Bogaert W, Danczak S, Bolla M et al (1992) Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol 25:231–241PubMedCrossRef

26.

Bensadoun RJ, Magne N, Marcy PY, Demard F (2001) Chemotherapy- and radiotherapy-induced mucositis in head and neck cancer patients: new trends in pathophysiology, prevention and treatment. Eur Arch Otorhinolaryngol 258:481–487PubMedCrossRef

27.

Awwad HK, Lotayef M, Shouman T, Begg AC, Wilson G, Bentzen SM, Abd El-Moneim H, Eissa S (2002) Accelerated hyperfractionation (AHF) compared to conventional fractionation (CF) in the postoperative radiotherapy of locally advanced head and neck cancer: influence of proliferation. Br J Cancer 86:517–523PubMedCentralPubMedCrossRef

28.

Zackrisson B, Mercke C, Strander H, Wennerberg J, Cavallin-Stahl E (2003) A systematic overview of radiation therapy effects in head and neck cancer. Acta Oncol 42:443–461PubMedCrossRef

Title: Influence of periodontitis on the experience of oral mucositis in cancer patients undergoing head and neck radiotherapy: a pilot study
Authors: Arlene Khaw
Sharon Liberali
Richard Logan
Dorothy Keefe
P. Mark Bartold
Publication date: 01-08-2014
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 8/2014
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-014-2186-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background and aim

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 8/2014

Breast cancer survivors’ perspectives on a weight loss and physical activity lifestyle intervention

Item response theory analysis of the patient satisfaction with cancer-related care measure: a psychometric investigation in a multicultural sample of 1,296 participants

Reduced intensity conditioning and oral care measures prevent oral mucositis and reduces days of hospitalization in allogeneic stem cell transplantation recipients

Influence of comorbidity on cancer patients’ rehabilitation needs, participation in rehabilitation activities and unmet needs: a population-based cohort study

Inappropriate referrals at the end of life—the existing Indian scenario

Effect of dance on cancer-related fatigue and quality of life

Keynote webinar | Spotlight on antibody–drug conjugates in cancer